Lymphomatoid papulosis

Summary

Lymphomatoid papulosis (MONDO:0020326) is a disease and 7 clinical trials. Top therapeutic interventions include brentuximab vedotin, bexarotene, and mechlorethamine. A subtype of primary cutaneous CD30+ T-cell lymphoproliferative disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Europe)
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lymphomatoid papulosis
Mondo ID	MONDO:0020326
MeSH	D017731
Orphanet	98842
ICD-11	1791207220
NCIT	C3721
SNOMED CT	31047003
UMLS	C0206182
MedGen	61534
GARD	0006944
MedDRA	10056670
Is cancer (heuristic)	no

Also known as: LYP · LyP

Disease family

Classification path: neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › non-Hodgkin lymphoma › T-cell non-Hodgkin lymphoma › primary cutaneous T-cell lymphoma › indolent primary cutaneous T-cell lymphoma › primary cutaneous CD30+ T-cell lymphoproliferative disease › lymphomatoid papulosis

Related subtypes (1): primary cutaneous anaplastic large cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01352520	PHASE2	ACTIVE_NOT_RECRUITING	SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
NCT03587844	PHASE2	RECRUITING	Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
NCT03409432	PHASE2	COMPLETED	Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
NCT03602157	PHASE1	ACTIVE_NOT_RECRUITING	Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
NCT02840747	Not specified	RECRUITING	Tissue Repository: CTCL Collection Protocol
NCT06207812	Not specified	RECRUITING	Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis
NCT05106192	Not specified	WITHDRAWN	Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BRENTUXIMAB VEDOTIN	4	3
BEXAROTENE	4	1
MECHLORETHAMINE	4	1